Cognitive Enhancement Research Compounds Compared: Semax, Selank, and NAD+ Precursors
“Cognitive enhancement” can mean better attention in a healthy participant, preserved memory during stress, improved function after neurological injury, or slower decline in a clinical population. Those are different outcomes, and a compound that is plausible for one should not automatically be described as effective for the others.
This comparison examines three research strategies that are often grouped together despite major differences: Semax, Selank, and NAD+ restoration through precursors such as nicotinamide riboside. Semax and Selank are synthetic peptides. NAD+ is a coenzyme rather than a peptide, but it belongs in the comparison because it represents a widely discussed metabolic approach to brain-aging research.
The most useful conclusion is not a universal ranking. It is a match between the proposed mechanism, the study population, and the cognitive endpoint being measured.
Quick Comparison
| Research question | Semax | Selank | NAD+ precursors |
|---|---|---|---|
| Primary research frame | Neurotrophic signaling and neuroprotection | Anxiety and stress modulation | Cellular energetics and age-related metabolism |
| Most relevant cognitive domain | Attention, learning, recovery-associated function | Performance impaired by anxiety or stress | Cognition in aging or metabolic dysfunction |
| Human evidence | Limited; includes small mechanistic and neuroimaging studies | Limited; mainly anxiety-focused clinical literature | Multiple human trials, but cognitive benefit remains inconsistent |
| Translational limitation | Much evidence is preclinical or condition-specific | Anxiolysis can be mistaken for direct enhancement | Raising NAD-related measures may not improve cognition |
| Best-fitting study design | Mechanism plus validated cognitive tasks | Anxiety measures plus cognitive tasks under stress | Biomarkers plus prespecified clinical cognitive outcomes |
Semax: A Neurotrophic and Neuroprotection Strategy
Semax is a synthetic fragment related to adrenocorticotropic hormone sequences, but it is studied primarily for central nervous system effects rather than for classic adrenal stimulation. Proposed mechanisms include changes in neurotrophic signaling, gene expression, monoaminergic systems, and responses to ischemic or inflammatory stress. The Semax mechanism page covers those pathways in more detail.
A human resting-state functional MRI study compared acute Semax, Selank, and placebo exposure in 52 healthy participants. It reported compound-related differences in connectivity involving the amygdala, temporal cortex, and regions relevant to executive function.[1] That is useful mechanistic evidence, but functional connectivity is not the same as a demonstrated improvement in memory, attention, or real-world performance.
Recent animal work has also tested Semax in disease models. In a transgenic mouse model of Alzheimer-like pathology, Semax and a derivative improved performance on behavioral tasks and reduced amyloid inclusions.[4] The result supports further investigation, but it cannot establish efficacy in people with Alzheimer disease or in healthy people seeking cognitive enhancement.
What Semax evidence can support
- a biologically plausible effect on central nervous system signaling
- further study of attention, learning, and recovery-associated endpoints
- experiments that pair molecular or neuroimaging markers with validated behavioral tasks
What it cannot yet support
- a general claim that Semax improves cognition in healthy adults
- direct extrapolation from stroke, injury, or transgenic animal models to everyday productivity
- a conclusion that a short-term imaging change predicts durable clinical benefit
Semax is therefore the strongest fit of the three when the research hypothesis is explicitly neurotrophic or neuroprotective. It is not automatically the best-supported option for broad enhancement.
Selank: Reducing Cognitive Interference Rather Than Directly “Boosting” Cognition
Selank is a synthetic analog of tuftsin and is usually framed as an anxiolytic research peptide. That distinction matters because anxiety can impair working memory, attention, and task persistence. Reducing anxiety-related interference may improve observed performance without directly increasing baseline cognitive capacity.
In the same 52-participant neuroimaging study, Selank and Semax produced both shared and distinct functional-connectivity effects.[1] The study demonstrates that the compounds are not neurologically inert and should not be treated as interchangeable, but it does not provide a head-to-head clinical ranking for cognitive performance.
A small comparative study in 60 patients with anxiety-spectrum disorders reported pronounced anxiolytic effects and mild nootropic effects with Selank.[2] The population, comparator, regional clinical context, and outcome reporting limit generalization. In particular, evidence from anxiety-disorder treatment does not show that Selank enhances cognition in healthy participants.
Where Selank fits best
Selank is most coherent when a protocol asks whether reducing anxiety or stress preserves performance. Useful outcomes could include:
- anxiety and stress scales measured alongside cognition
- working-memory or attention tasks performed under controlled stress
- error rates, response variability, or task persistence
- separation of sedation, anxiolysis, and direct cognitive effects
For compound-specific limitations, see the Selank evidence review and Selank safety overview.
The key interpretation risk
If a participant performs better because anxiety decreased, the result is meaningful, but it should be labeled correctly. It is evidence for relief of a performance constraint, not necessarily evidence that memory capacity or executive function was directly enhanced.
NAD+ Precursors: A Metabolic Approach With More Human Testing
NAD+ is essential to cellular redox reactions and is connected to mitochondrial function, DNA-repair enzymes, and sirtuin biology. Unlike Semax and Selank, it is not a peptide. Research usually attempts to influence the system with precursors such as nicotinamide riboside or nicotinamide mononucleotide rather than treating NAD+ as a receptor agonist.
The advantage of this category is that human randomized trials can measure both target engagement and cognition. The disadvantage is that those two outcomes do not necessarily move together.
In a randomized, double-blind crossover study of older adults with subjective cognitive decline or mild cognitive impairment, eight weeks of nicotinamide riboside was well tolerated and changed a plasma Alzheimer-related biomarker, but it did not significantly improve the study’s conventional or digital cognitive outcomes.[3] This is an important negative distinction: a biomarker signal can justify further research without demonstrating cognitive enhancement.
NAD+ precursors fit best when the hypothesis involves aging, energy metabolism, or mitochondrial dysfunction. Researchers should predefine whether the primary outcome is biochemical target engagement, disease-related biomarkers, or actual cognitive performance. For pathway context, see Mitochondrial Biogenesis and the NAD+ research guide.
Comparing Evidence Strength Without Overstating It
The evidence base is uneven, so a single “winner” would be misleading.
Human cognitive outcomes
NAD+ precursors have been tested in more conventional human trial designs, including older and cognitively vulnerable populations. However, more human testing does not equal proven benefit, and at least one controlled study found biomarker movement without cognitive improvement.[3]
Selank has limited clinical literature, but much of it concerns anxiety disorders rather than direct enhancement. Semax has human mechanistic work and a broader preclinical neuroprotection literature, yet the gap between mechanism and repeatable cognitive benefit remains substantial.
Mechanistic specificity
Semax offers the clearest direct neurotrophic and neuroprotection hypothesis. Selank offers the clearest anxiety-mediated performance hypothesis. NAD+ precursors offer the clearest metabolic and brain-aging hypothesis.
The correct comparison is therefore conditional:
- For neurotrophic or injury-recovery research: Semax is the most directly aligned candidate.
- For anxiety-limited performance: Selank provides the more coherent hypothesis.
- For age-related metabolic dysfunction: NAD+ precursor research has the strongest design fit.
- For enhancement in healthy adults: none has sufficiently strong evidence to justify confident efficacy claims.
Why Endpoint Selection Changes the Answer
A cognitive study can appear positive or negative depending on what it measures. Researchers should distinguish at least four layers.
1. Target engagement
Examples include a change in NAD-related metabolites, gene expression, or a receptor-linked signal. Target engagement shows that a compound reached or influenced a biological system. It does not prove cognitive benefit.
2. Mechanistic biomarkers
Functional connectivity, neurotrophic markers, inflammatory mediators, and disease-associated plasma markers can support a biological hypothesis. They remain surrogate outcomes unless validated against meaningful cognitive change.
3. Cognitive task performance
Memory, attention, processing speed, and executive function should be measured with validated tasks and prespecified analyses. Practice effects, sleep, anxiety, and expectancy can all distort results.
4. Clinical or functional benefit
The highest bar is improvement that matters outside a single task: daily function, recovery, reduced impairment, or a durable change in disease trajectory. None of the three strategies has established broad functional enhancement across populations.
Research Design Considerations
Match the population to the hypothesis
Healthy participants, people under acute stress, post-injury populations, and adults with mild cognitive impairment should not be combined conceptually. Baseline impairment can create more room for improvement, while a ceiling effect may obscure changes in healthy participants.
Use active controls when possible
For an anxiolytic candidate such as Selank, an active control can help separate reduced anxiety from nonspecific expectancy. For metabolic interventions, biochemical confirmation can show whether a null cognitive result reflects failed target engagement or a genuine disconnect between metabolism and performance.
Predefine the cognitive domain
“Cognition” is too broad as a sole endpoint. A protocol should specify memory, sustained attention, working memory, processing speed, learning, or executive control before data collection.
Separate acute from durable effects
An acute connectivity change and an eight-week clinical outcome answer different questions. Follow-up measurements are needed before describing an effect as persistent.
Avoid route and exposure assumptions
Peptides and NAD+ precursors have different stability, pharmacokinetics, and tissue-exposure constraints. Apparent differences may reflect delivery and exposure rather than the underlying mechanism. The site’s Central Nervous System research page provides useful tissue-level context.
Safety and Regulatory Context
A favorable signal in a small or short study is not comprehensive safety evidence. Semax and Selank lack the large, diverse, long-duration trial programs expected for widely established therapies. NAD+ precursors have more oral human exposure data, but long-term safety and efficacy can still depend on population, formulation, and outcome.
These compounds should also not be grouped as if they share one risk profile. A neuroactive peptide, an anxiolytic peptide, and a metabolic precursor can differ in purity concerns, delivery constraints, interactions, and plausible adverse effects. Research-grade evidence does not substitute for clinical approval or individualized medical evaluation.
Bottom Line
Semax, Selank, and NAD+ precursors represent three different cognitive research models rather than three interchangeable nootropics.
Semax is best aligned with neurotrophic and neuroprotection hypotheses, but much of the efficacy argument remains preclinical or mechanistic. Selank is best aligned with anxiety and stress-related performance, where an apparent cognitive benefit may result from removing interference rather than directly increasing capacity. NAD+ precursors have a larger human-trial footprint and strong metabolic rationale, but controlled data show that biomarker changes can occur without measurable cognitive improvement.
For healthy-adult cognitive enhancement, the evidence is not strong enough to declare a winner. The most evidence-based approach is to choose a defined population, state a mechanism-specific hypothesis, and measure both biological target engagement and a prespecified cognitive outcome.
Related Research
- Semax Research Guide — compound overview and research framing for Semax
- Semax Mechanism — neurotrophic, monoaminergic, and gene-expression hypotheses
- Selank Research Guide — compound overview focused on anxiolytic research
- Selank Evidence Review — closer examination of the available evidence base
- NAD+ Research Guide — metabolic context for NAD+ restoration strategies
- Central Nervous System — tissue-level context for neuroactive peptide research
- Mitochondrial Biogenesis — pathway background for metabolic and brain-aging hypotheses
- Semax vs Selank — focused head-to-head comparison of the two neuroactive peptides
Sources
[1] https://pubmed.ncbi.nlm.nih.gov/32342318 — Functional Connectomic Approach to Studying Selank and Semax Effects [2] https://pubmed.ncbi.nlm.nih.gov/25176261 — Comparison of Selank and phenazepam in anxiety disorders [3] https://pubmed.ncbi.nlm.nih.gov/39817194 — Cognitive and biomarker effects of nicotinamide riboside [4] https://pubmed.ncbi.nlm.nih.gov/41479572 — Semax in an animal model of Alzheimer disease